Therapy News and Research

RSS

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

Saint Luke receives $3.4M to investigate health benefits, cost-effectiveness of novel cardiac procedures

aint Luke's Mid America Heart Institute has been awarded a $3.4 million, three-year grant from Boston Scientific to investigate and better define the success, safety, health benefits, and cost-effectiveness of novel methods to open challenging blocked coronary arteries previously thought untreatable through minimally invasive techniques.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

New versions of old antibiotic offers strategy for overcoming drug resistance

Research led by St. Jude Children's Research Hospital scientists has produced new versions of an old antibiotic that are active against difficult-to-treat tuberculosis; offers new strategy for overcoming drug resistance

28 Jan 2014

Use of smartphones and tablets to search for prescription drug information rising rapidly

Decision Resources Group finds the number of US consumers that are using their smartphones and tablets to search for prescription drug information is rising rapidly, according to data from ePharma Consumer 2013, while searches through desktops and laptops is beginning to wane, reinforcing the need for prescription drug marketers to prioritize mobile investments.

28 Jan 2014

Researchers find novel drug combination approach to speed fight against cancer

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way.

27 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Single-pill combination antihypertensives have mixed adherence effects

Switching to single-pill combination antihypertensives results in marked improvements in medication adherence, except for in a subset of patients for whom the strategy may backfire, say researchers.

27 Jan 2014

Study demonstrates direct effects of fragmented sleep on tumor growth

Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.

27 Jan 2014

New method allows for large-scale generation of human embryonic stem cells

A new method allows for large-scale generation of human embryonic stem cells of high clinical quality. It also allows for production of such cells without destroying any human embryos.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

Music therapy interventions may provide essential psychosocial support to young patients with cancer

A new study has found that adolescents and young adults undergoing cancer treatment gain coping skills and resilience-related outcomes when they participate in a therapeutic music process that includes writing song lyrics and producing videos.

27 Jan 2014

MGH Institute of Health Professions proposes to add new MPAS program

MGH Institute of Health Professions plans to add a Master of Physician Assistant Studies (MPAS) program to its menu of health professions degrees beginning in May 2015.

27 Jan 2014

Most high-risk CV devices approved without clinical data

Many cardiac implantable electronic device models currently in use were approved via a Food and Drug Administration review process in which the models were assumed safe and effective based on approval of prior versions of the device, according to a study in the January 22/29 issue of JAMA.

From Medtronic 27 Jan 2014

Hols conveys product’s safety and cost effectiveness to managed care groups

Health Outcomes Liaisons (HOLs) play a critical role in conveying a therapy's safety and cost effectiveness to managed care groups. With billions in sales riding on effectively communicating with these organizations regarding products' cost effectiveness and safety, the biopharmaceutical industry has turned to HOLs to fill this critical communication role.

27 Jan 2014

Landmark study reveals positive effects of music therapy among youth undergoing cancer treatment

A ground-breaking collaborative multi-site study found that teens and young adults undergoing the rigors of stem cell transplantation as part of cancer treatment gain coping skills and resilience-related outcomes when participating with a board certified music therapist in a therapeutic music protocol that includes writing song lyrics and producing videos. s.

27 Jan 2014

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

26 Jan 2014

Scientists provide new insights into molecular regulation of stem cell differentiation

The findings of the scientists of the Institute of Diabetes and Regeneration Research (IDR) at Helmholtz Zentrum München (HMGU) provide new insights into the molecular regulation of stem cell differentiation.

25 Jan 2014

Therapy News and Research

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Saint Luke receives $3.4M to investigate health benefits, cost-effectiveness of novel cardiac procedures

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

New versions of old antibiotic offers strategy for overcoming drug resistance

Use of smartphones and tablets to search for prescription drug information rising rapidly

Researchers find novel drug combination approach to speed fight against cancer

S. pneumoniae predicts acute sinusitis microbial response

Single-pill combination antihypertensives have mixed adherence effects

Study demonstrates direct effects of fragmented sleep on tumor growth

New method allows for large-scale generation of human embryonic stem cells

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

Music therapy interventions may provide essential psychosocial support to young patients with cancer

MGH Institute of Health Professions proposes to add new MPAS program

Most high-risk CV devices approved without clinical data

Hols conveys product’s safety and cost effectiveness to managed care groups

Landmark study reveals positive effects of music therapy among youth undergoing cancer treatment

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Scientists provide new insights into molecular regulation of stem cell differentiation

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News